Cynthia Gagnon

List of Publications by Year in Descending Order

92 papers	1,319 citations	21 h-index	31 g-index
108 ext. papers	1,714 ext. citations	3 avg, IF	4.65 L-index

#	Paper	IF	Citations
92	Monitoring changes in physical activity data during strength training of people with myotonic dystrophy type 1. *Procedia Computer Science*, **2022**, 198, 51-58	1.6	
91	Reliability and validity of digital health metrics for assessing arm and hand impairments in an ataxic disorder.. *Annals of Clinical and Translational Neurology*, **2022**,	5.3	1
90	Participation and Functional Independence in Adults With Recessive Spastic Ataxia of Charlevoix-Saguenay.. *Canadian Journal of Occupational Therapy*, **2022**, 84174221088417	1.4	
89	Functional mobility in walking adult population with ataxia of Charlevoix-Saguenay. *Orphanet Journal of Rare Diseases*, **2021**, 16, 432	4.2	0
88	Characterization of cannabis use by patients with myotonic dystrophy type 1: A pilot study. *Neuromuscular Disorders*, **2021**, 31, 226-231	2.9	1
87	Accomplishment of instrumental activities of daily living and its relationship with cognitive functions in adults with myotonic dystrophy type 1 childhood phenotype: an exploratory study. *BMC Psychology*, **2021**, 9, 56	2.8	1
86	Responsiveness of Daytime Sleepiness and Fatigue Scales in Myotonic Dystrophy Type 1. *Canadian Journal of Neurological Sciences*, **2021**, 1-4	1	1
85	Assessment of muscular strength and functional capacity in the juvenile and adult myotonic dystrophy type 1 population: a 3-year follow-up study. *Journal of Neurology*, **2021**, 268, 4221-4237	5.5	0
84	Nutritional Risk in Oculopharyngeal Muscular Dystrophy: Beyond Dysphagia. *Canadian Journal of Dietetic Practice and Research*, **2021**, 82, 95-97	1.3	
83	The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. *Frontiers in Neurology*, **2021**, 12, 677551	4.1	1
82	Cross-cultural adaptation of the SWAL-QOL and the Sydney Swallow Questionnaire (SSQ) into French-Canadian and preliminary assessment for their use in an oculopharyngeal muscular dystrophy (OPMD) population. *Quality of Life Research*, **2021**, 1	3.7	
81	Effects and Acceptability of an Individualized Home-Based 10-Week Training Program in Adults with Myotonic Dystrophy Type 1. *Journal of Neuromuscular Diseases*, **2021**, 8, 137-149	5	4
80	Acti-DM1: Monitoring the Activity Level of People With Myotonic Dystrophy Type 1 Through Activity and Exercise Recognition. *IEEE Access*, **2021**, 9, 49960-49973	3.5	1
79	Wheelchair mobility, motor performance and participation of adult wheelchair users with ARSACS: a cross-sectional study. *Disability and Rehabilitation: Assistive Technology*, **2020**, 1-8	1.8	1
78	Predictors of participation restriction over a 9-year period in adults with myotonic dystrophy type 1. *Disability and Rehabilitation*, **2020**, 1-17	2.4	1
77	Validity of the Mini-BESTest in adults with myotonic dystrophy type 1. *Muscle and Nerve*, **2020**, 62, 95-102	3.4	1
76	A data-driven framework for selecting and validating digital health metrics: use-case in neurological sensorimotor impairments. *Npj Digital Medicine*, **2020**, 3, 80	15.7	17

75	A study of impairments in oculopharyngeal muscular dystrophy. *Muscle and Nerve*, **2020**, 62, 201-207	3.4	5
74	Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1. *Journal of Neurology*, **2020**, 267, 461-468	5.5	12
73	Understanding factors hampering activities of daily living performance in childhood-onset myotonic dystrophy phenotypes. *Developmental Medicine and Child Neurology*, **2020**, 62, 665	3.3	
72	Measurement properties of wheelchair use assessment tools in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay. *Disability and Rehabilitation: Assistive Technology*, **2020**, 1-9	1.8	1
71	Documenting the psychometric properties of the scale for the assessment and rating of ataxia to advance trial readiness of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay. *Journal of the Neurological Sciences*, **2020**, 417, 117050	3.2	1
70	Is IDDSI an Evidence-Based Framework? A Relevant Question for the Frail Older Population. *Geriatrics (Switzerland)*, **2020**, 5,	2.2	6
69	DNA methylation at the gene locus is associated with cognitive functions in myotonic dystrophy type 1. *Epigenomics*, **2020**, 12, 2051-2064	4.4	7
68	Rehabilitation needs of youth with arthrogryposis multiplex congenita: Perspectives from key stakeholders. *Disability and Rehabilitation*, **2020**, 42, 2318-2324	2.4	9
67	The DM-scope registry: a rare disease innovative framework bridging the gap between research and medical care. *Orphanet Journal of Rare Diseases*, **2019**, 14, 122	4.2	1
66	Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes. *Human Molecular Genetics*, **2019**, 28, 2245-2254	5.6	23
65	What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review. *BMC Musculoskeletal Disorders*, **2019**, 20, 101	2.8	13
64	Expanding the clinical description of autosomal recessive spastic ataxia of Charlevoix-Saguenay. *Journal of the Neurological Sciences*, **2019**, 400, 39-41	3.2	8
63	Progressive Decline in Daily and Social Activities: A 9-year Longitudinal Study of Participation in Myotonic Dystrophy Type 1. *Archives of Physical Medicine and Rehabilitation*, **2019**, 100, 1629-1639	2.8	10
62	Training program-induced skeletal muscle adaptations in two men with myotonic dystrophy type 1. *BMC Research Notes*, **2019**, 12, 526	2.3	2
61	Development and validation of a disease severity index for ataxia of Charlevoix-Saguenay. *Neurology*, **2019**, 93, e1543-e1549	6.5	8
60	Patient-reported disease burden in oculopharyngeal muscular dystrophy. *Muscle and Nerve*, **2019**, 60, 724-731	3.4	3
59	gene DNA methylation levels are associated with muscular and respiratory profiles in DM1. *Neurology: Genetics*, **2019**, 5, e338	3.8	14
58	The requirement for a disease-specific patient-reported outcome measure of dysphagia in oculopharyngeal muscular dystrophy. *Muscle and Nerve*, **2019**, 59, 445-450	3.4	4

57	Comparison of two methods to categorize thickened liquids for dysphagia management in a clinical care setting context: The Bostwick consistometer and the IDDSI Flow Test. Are we talking about the same concept?. *Journal of Texture Studies*, **2019**, 50, 95-103	3.6	13
56	Validity and Reliability of Outcome Measures Assessing Dexterity, Coordination, and Upper Limb Strength in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay. *Archives of Physical Medicine and Rehabilitation*, **2018**, 99, 1747-1754	2.8	11
55	Reliability of the Apathy Evaluation Scale in Myotonic Dystrophy Type´1. *Journal of Neuromuscular Diseases*, **2018**, 5, 39-46	5	1
54	Assessing mobility and balance in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay population: Validity and reliability of four outcome measures. *Journal of the Neurological Sciences*, **2018**, 390, 4-9	3.2	10
53	Relationships between Lower Limb Muscle Strength Impairments and Physical Limitations in DM1. *Journal of Neuromuscular Diseases*, **2018**, 5, 215-224	5	8
52	Responsiveness of performance-based outcome measures for mobility, balance, muscle strength and manual dexterity in adults with myotonic dystrophy type 1. *Journal of Rehabilitation Medicine*, **2018**, 50, 269-277	3.4	8
51	Myotonic dystrophy type 1: reasons to be OPTIMISTIC. *Lancet Neurology, The*, **2018**, 17, 652-653	24.1	5
50	French translation and cross-cultural adaptation of The Myotonic Dystrophy Health Index. *Muscle and Nerve*, **2018**, 57, 686-689	3.4	3
49	From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay. *Orphanet Journal of Rare Diseases*, **2018**, 13, 165	4.2	10
48	Adaptation transculturelle en fran□ais du Edinburgh Feeding Evaluation in Dementia (EdFED) Scale : un questionnaire pour ˆvaluer les difficult□s ˆ sˆalimenter de personnes □g□es pr□sentant des troubles cognitifs en centre d'h□bergement. *Canadian Journal on Aging*, **2018**, 37, 474-481	1.6	2
47	Consensus-based care recommendations for adults with myotonic dystrophy type 1. *Neurology: Clinical Practice*, **2018**, 8, 507-520	1.7	65
46	An exploratory natural history of ataxia of Charlevoix-Saguenay: A 2-year follow-up. *Neurology*, **2018**, 91, e1307-e1311	6.5	9
45	A 9-year follow-up study of quantitative muscle strength changes in myotonic dystrophy type 1. *Journal of Neurology*, **2018**, 265, 1698-1705	5.5	22
44	Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). *Journal of Neurology*, **2018**, 265, 2060-2070	5.5	12
43	Is one trial enough for repeated testing? Same-day assessments of walking, mobility and fine hand use in people with myotonic dystrophy type 1. *Neuromuscular Disorders*, **2017**, 27, 153-158	2.9	6
42	Measurement properties of a new wireless electrogoniometer for quantifying spasticity during the pendulum test in ARSACS patients. *Journal of the Neurological Sciences*, **2017**, 375, 181-185	3.2	2
41	Further evidence for the reliability and validity of the Fatigue and Daytime Sleepiness Scale. *Journal of the Neurological Sciences*, **2017**, 375, 23-26	3.2	14
40	CpG Methylation, a Parent-of-Origin Effect for Maternal-Biased Transmission of Congenital Myotonic Dystrophy. *American Journal of Human Genetics*, **2017**, 100, 488-505	11	48

39	Validity and reliability of the LEMOCOT in the adult ARSACS population: A measure of lower limb coordination. *Journal of the Neurological Sciences*, **2017**, 377, 193-196	3.2	12
38	Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation-Sponsored Workshop. *Therapeutic Innovation and Regulatory Science*, **2017**, 51, 516-522	1.2	2
37	A 9-year follow-up study of the natural progression of upper limb performance in myotonic dystrophy type 1: A similar decline for phenotypes but not for gender. *Neuromuscular Disorders*, **2017**, 27, 673-682	2.9	10
36	Facilitating orphan drug development: Proceedings of the TREAT-NMD International Conference, December 2015, Washington, DC, USA. *Neuromuscular Disorders*, **2017**, 27, 693-701	2.9	1
35	Lower limb muscle strength impairment in late-onset and adult myotonic dystrophy type 1 phenotypes. *Muscle and Nerve*, **2017**, 56, 57-63	3.4	14
34	A recessive ataxia diagnosis algorithm for the next generation sequencing era. *Annals of Neurology*, **2017**, 82, 892-899	9.4	20
33	Traduction française de l'échelle Charcot-Marie-Tooth Disease Pediatric Scale. *Canadian Journal of Neurological Sciences*, **2017**, 44, 740-743	1	4
32	Computer-based assessment of upper-limb incoordination in autosomal recessive spastic ataxia of Charlevoix-Saguenay patients: A pilot study. *Journal of the Neurological Sciences*, **2017**, 380, 68-73	3.2	3
31	Participation restriction in childhood phenotype of myotonic dystrophy type 1: a systematic retrospective chart review. *Developmental Medicine and Child Neurology*, **2017**, 59, 291-296	3.3	10
30	Predictors of Comorbid Eating Disorders and Diabetes in People with Type 1 and Type 2 Diabetes. *Canadian Journal of Diabetes*, **2017**, 41, 52-57	2.1	17
29	Cognitive decline over time in adults with myotonic dystrophy type 1: A 9-year longitudinal study. *Neuromuscular Disorders*, **2017**, 27, 61-72	2.9	42
28	A Scoping Review of Clinical Practice Improvement Methodology Use in Rehabilitation. *Rehabilitation Process and Outcome*, **2016**, 5, RPO.S20360	0.5	1
27	Stanford Chronic Disease Self-Management Program in myotonic dystrophy: New opportunities for occupational therapists: Stanford Chronic Disease Self-Management Program dans la dystrophie myotonique : De nouvelles opportunités pour les ergothérapeutes. *Canadian Journal of Occupational Therapy*, **2016**, 83, 166-76	1.4	4
26	Assessing upper extremity capacity as a potential indicator of needs related to household activities for rehabilitation services in people with myotonic dystrophy type 1. *Neuromuscular Disorders*, **2015**, 25, 522-9	2.9	6
25	Prevalence and correlates of apathy in myotonic dystrophy type 1. *BMC Neurology*, **2015**, 15, 148	3.1	43
24	Lower limb muscle impairment in myotonic dystrophy type 1: the need for better guidelines. *Muscle and Nerve*, **2015**, 51, 473-8	3.4	9
23	Psychological characteristics of patients with myotonic dystrophy type 1. *Acta Neurologica Scandinavica*, **2015**, 132, 49-58	3.8	18
22	Consensus on cerebral involvement in myotonic dystrophy: workshop report: May 24-27, 2013, Ferrere (AT), Italy. *Neuromuscular Disorders*, **2014**, 24, 445-52	2.9	33

21	Cognitive Deficits Associated with Sleep Apnea in Myotonic Dystrophy Type 1. *Journal of Neuromuscular Diseases*, **2014**, 1, 95-98	5	6
20	The Virtual Peg Insertion Test as an assessment of upper limb coordination in ARSACS patients: a pilot study. *Journal of the Neurological Sciences*, **2014**, 347, 341-4	3.2	19
19	Cognitive Deficits Associated with Sleep Apnea in Myotonic Dystrophy Type 1. *Journal of Neuromuscular Diseases*, **2014**, 1, 95-98	5	3
18	Evaluating the integration of chronic disease prevention and management services into primary health care. *BMC Health Services Research*, **2013**, 13, 132	2.9	31
17	Daytime sleepiness and myotonic dystrophy. *Current Neurology and Neuroscience Reports*, **2013**, 13, 340	6.6	52
16	Report of the first Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011. *Neuromuscular Disorders*, **2013**, 23, 1056-68	2.9	32
15	Effect of rehabilitation length of stay on outcomes in individuals with traumatic brain injury or spinal cord injury: a systematic review protocol. *Systematic Reviews*, **2013**, 2, 59	3	4
14	Clinical, psychosocial, and central correlates of quality of life in myotonic dystrophy type 1 patients. *European Neurology*, **2013**, 70, 308-15	2.1	38
13	Prevalence of lifestyle risk factors in myotonic dystrophy type 1. *Canadian Journal of Neurological Sciences*, **2013**, 40, 42-7	1	21
12	Comorbid diabetes and eating disorders in adult patients: assessment and considerations for treatment. *The Diabetes Educator*, **2012**, 38, 537-42	2.5	21
11	Utilisation d'un plan de soins intégrés pour le développement du rôle de l'infirmière dans le suivi des personnes atteintes de dystrophie myotonique. *Recherche En Soins Infirmiers*, **2011**, N° 106, 77	0.5	
10	Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. *Neuromuscular Disorders*, **2010**, 20, 847-51	2.9	53
9	The potential of disease management for neuromuscular hereditary disorders. *Rehabilitation Nursing*, **2009**, 34, 118-26	1.3	8
8	Predictors of disrupted social participation in myotonic dystrophy type 1. *Archives of Physical Medicine and Rehabilitation*, **2008**, 89, 1246-55	2.8	70
7	Life habits in myotonic dystrophy type 1. *Acta Dermato-Venereologica*, **2007**, 39, 560-6	2.2	34
6	Towards an integrative approach to the management of myotonic dystrophy type 1. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 800-6	5.5	37
5	Measurement of participation in myotonic dystrophy: reliability of the LIFE-H. *Neuromuscular Disorders*, **2006**, 16, 262-8	2.9	16
4	Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1403-5	5.5	61

3	Standardized finger-nose test validity for coordination assessment in an ataxic disorder. *Canadian Journal of Neurological Sciences*, **2004**, 31, 484-9	1	31
2	Autosomal recessive spastic ataxia of Charlevoix-Saguenay: upper extremity aptitudes, functional independence and social participation. *International Journal of Rehabilitation Research*, **2004**, 27, 253-6	1.8	14
1	An Objective Technology-based Assessment of Arm and Hand Sensorimotor Disability in Neurological Disorders		1